Peer-influenced content. Sources you trust. No registration required. This is HCN.
Although timely access to the results of studies evaluating patients with cancer infected with COVID-19 is urgently needed, such evidence is currently very limited. The CCC19 hopes to change all of that.
Allergy & Immunology April 20th 2020
According to a recent study published in Journal of Infectious Diseases, an analysis of four different coronaviruses (OC43, 229E, HKU1 and NL63) over an 8-year period demonstrated that they were detected in a limited timeframe, from December to April and May, with a peak during January and February.
JAMA Network
Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.
The University of Nebraska Medical Center’s innovative decontamination procedure involving the delivery of ultraviolet germicidal irradiation to used N95 masks has shown great promise in the fight against the shortage of PPEs.
Allergy & Immunology April 13th 2020
A comprehensive guide from the American Medical Association (AMA), which includes information for those who want to support communities severely impacted by COVID-19, including the how and where to volunteer and all things to consider.
Annals of Internal Medicine
Data to support the use of hydroxychloroquine (HCQ) and chloroquine (CQ) for COVID-19 are limited and inconclusive; this article from the American College of Physicians (ACP) discusses the facts to arm yourself with the proper information.